Minerva urology and nephrology · 2025
A drug-coated balloon treatment for urethral stricture: preliminary experience in an Italian real-life cohort.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castellucci Roberto, Morselli Simone, Gatti Lorenzo, Ferrari Giovanni, Secco Silvia, Scarcia Marcello, Ludovico Giuseppe M, Spirito Lorenzo, Imperatore Vittorio, Preto Mirko, Gontero Paolo, Persico Francesco, Fedelini Paolo, Trama Francesco, Lauro Giovanni Di, Dini Danilo, DE Marco Ferdinando, Cindolo Luca
Аннотация
BACKGROUND: Urethral stricture is an abnormal narrowing of the urethra and occurs in anterior urethra for 92% of cases. Although open surgery is considered the gold standard for this type of disease, endoscopic procedures are the most commonly used. The Optilume® Drug Coated Balloon (DCB) (Urotronic, Inc., Plymouth, MN, USA) is the first DCB intended for the treatment of male urethral strictures. Here we report the results of a multicenter Italian real-life study.
METHODS: We collected data from nine Italian centers. Patients with urethral strictures or bladder neck stricture were treated with the Optilume© DCB. We evaluated variation in IPSS, QoL and IIEF5 score, QMax, PVR, and freedom from repeat intervention.
RESULTS: Overall, 130 subjects were treated; median follow-up was six months. Mean age and prostate volume were 64 and 45 mL. Total median operative time was 15 minutes whereas the median time of Optilume application was 7 minutes. IPSS and QoL changed from a mean of 24 and 4 points at baseline to 10 and 1 points respectively at the last follow-up (P<0.001). We have also recorded a significant improvement in Qmax and PVR from 8 mL/s and 100 mL at baseline to 17.8 mL/s and 0 mL at the last follow-up (P<0.001). Intra and post operative not serious complications occurred in 3 and 10 patients, respectively. Six patients underwent reoperation during follow-up.
CONCLUSIONS: In our experience, the Optilume© represents a valid option in the management of patients with urethral stricture, with or without previous surgery.
METHODS: We collected data from nine Italian centers. Patients with urethral strictures or bladder neck stricture were treated with the Optilume© DCB. We evaluated variation in IPSS, QoL and IIEF5 score, QMax, PVR, and freedom from repeat intervention.
RESULTS: Overall, 130 subjects were treated; median follow-up was six months. Mean age and prostate volume were 64 and 45 mL. Total median operative time was 15 minutes whereas the median time of Optilume application was 7 minutes. IPSS and QoL changed from a mean of 24 and 4 points at baseline to 10 and 1 points respectively at the last follow-up (P<0.001). We have also recorded a significant improvement in Qmax and PVR from 8 mL/s and 100 mL at baseline to 17.8 mL/s and 0 mL at the last follow-up (P<0.001). Intra and post operative not serious complications occurred in 3 and 10 patients, respectively. Six patients underwent reoperation during follow-up.
CONCLUSIONS: In our experience, the Optilume© represents a valid option in the management of patients with urethral stricture, with or without previous surgery.